Skip to content
10-Q

Quarterly Report

POINT BIOPHARMA GLOBAL INC.

0001811764-22-000085

← back to feed
Filed
Nov 14, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2022 · Nov 9, 2022 105.64M sh
Short Term Investments Q3 2022 · Sep 30, 2022 $165.74M
Short Term Investments Q3 2022 · Dec 31, 2021 $0
Cash And Equivalents Q3 2022 · Sep 30, 2022 $125.78M
Cash And Equivalents Q3 2022 · Dec 31, 2021 $238.82M
Current Liabilities Q3 2022 · Sep 30, 2022 $16.61M
Current Liabilities Q3 2022 · Dec 31, 2021 $7.98M
Total Liabilities Q3 2022 · Sep 30, 2022 $16.61M
Total Liabilities Q3 2022 · Dec 31, 2021 $8.05M
Current Assets Q3 2022 · Sep 30, 2022 $296.23M
Current Assets Q3 2022 · Dec 31, 2021 $243.85M
Total Assets Q3 2022 · Sep 30, 2022 $325.69M
Total Assets Q3 2022 · Dec 31, 2021 $263.26M
Shares Diluted Q3 2022 · Sep 30, 2021 90.12M sh
Shares Diluted Q3 2022 · Sep 30, 2021 68.32M sh
Dividends Paid Q3 2022 · Sep 30, 2021 $0
Capex restated Q3 2022 · Sep 30, 2021 $6.32M
Operating Cash Flow restated Q3 2022 · Sep 30, 2021 −$33.17M
Eps Diluted Q3 2022 · Sep 30, 2021 −$0.19
Eps Diluted Q3 2022 · Sep 30, 2021 −$0.46
Eps Basic Q3 2022 · Sep 30, 2021 −$0.19
Eps Basic Q3 2022 · Sep 30, 2021 −$0.46
Sga Expense Q3 2022 · Sep 30, 2021 $4.03M
Sga Expense Q3 2022 · Sep 30, 2021 $7.44M
Rd Expense Q3 2022 · Sep 30, 2021 $13M
Rd Expense Q3 2022 · Sep 30, 2021 $23.97M
Net Income Q3 2022 · Sep 30, 2021 −$17.12M
Net Income Q3 2022 · Sep 30, 2021 −$31.71M
Net Income Q3 2022 · Jun 30, 2021 −$8.8M
Net Income Q3 2022 · Mar 31, 2021 −$5.78M
Operating Income Q3 2022 · Sep 30, 2021 −$17.03M
Operating Income Q3 2022 · Sep 30, 2021 −$31.42M